| Literature DB >> 28704546 |
Nana Ama Amissah1,2, Lieke van Dam3, Anthony Ablordey2, Opoku-Ware Ampomah4, Isaac Prah2, Caitlin S Tetteh2, Tjip S van der Werf1, Alexander W Friedrich3, John W Rossen3, Jan Maarten van Dijl3, Ymkje Stienstra1.
Abstract
BACKGROUND: In developing countries, hospitalized burn victims are at high risk of nosocomial infections caused by Staphylococcus aureus. Risk factors include poor infection control practices, prolonged hospitalisation and limited capacity for laboratory microbiological analyses. These problems are compounded by widespread use of antibiotics that drives the spread of multi-drug resistant bacteria.Entities:
Mesh:
Year: 2017 PMID: 28704546 PMCID: PMC5509299 DOI: 10.1371/journal.pone.0181072
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics.
| Patient characteristics | Number (IQR or % frequency) |
|---|---|
| Sex (female, percentage) | 37 (60%) |
| Age (years, median (IQR)) | 25 (3–35) |
| Type of burn | |
| Acid | 1 (1.6%) |
| Chemicals | 2 (3.2%) |
| Electrical | 1 (1.6%) |
| Flame | 24 (38.7%) |
| Gas | 16 (25.8%) |
| Scald (hot fluids) | 18 (29%) |
| TBSA (median %) | 15 (7.8–28.2) |
| Hospital stay (days) | 11 (5–17.5) |
| In-hospital mortality | 15 (24.2%) |
*Hospital stay refers exclusively to hospitalization in the burn unit
Number of days of antibiotics prescribed per 100 days in the burn unit and antibiotic resistances of the 80 investigated S. aureus isolates.
| Antibiotics | Number of days of antibiotic used per 100 in-patient hospital days | No. (resistance rate %) |
|---|---|---|
| Amoxicillin-clavulanic acid | 1.9 | |
| Cefuroxime | 60.6 | |
| Ceftazidime | 1.6 | |
| Benzylpenicillin | - | 80 (100) |
| Oxacillin | - | 22 (28) |
| Vancomycin | 0.4 | 0 (0) |
| Gentamicin | 11.9 | 21 (26) |
| Tobramycin | - | 21 (26) |
| Kanamycin | - | 22 (28) |
| Ciprofloxacin | 5.6 | 21 (26) |
| Levofloxacin | 4.1 | - |
| Chloramphenicol | - | 35 (44) |
| Clindamycin | - | 1 (1) |
| Erythromycin | 2.3 | 1 (1) |
| Fosfomycin | - | 0 (0) |
| Fusidic acid | - | 0 (0) |
| Mupirocin | - | 0 (0) |
| Linezolid | - | 0 (0) |
| Teicoplanin | - | 0 (0) |
| Rifampicin | - | 1 (1) |
| Tetracycline | - | 41 (51) |
| Trimethoprim/sulfamethoxazole | - | 20 (25) |
| Metronidazole | 2.9 | - |
| 91.2 |
“-” indicates that antibiotics were not prescribed to burn patients or that the resistance of S. aureus to the respective antibiotics was not tested.
Antibiotic resistance profiles and detection of PVL genes in S. aureus isolates with different spa-types.
| ST | No. of isolates | Major antibiograms | PVL-positive | |
|---|---|---|---|---|
| t008 | 8, 2021 | 5 | Ben | 0 |
| t024 | 8 | 1 | Ben | 0 |
| t084 | 15, 3249, - | 10 | Ben, tri/sulf | 7 |
| t127 | 1, 3248 | 5 | Ben | 0 |
| t1816 | 15 | 3 | Ben, tri/sulf | 2 |
| t2055 | 2434 | 1 | Ben, tet, chl, tri/sulf | 0 |
| t304 | 6 | 1 | Ben | 0 |
| t311 | 5 | 2 | Ben, tet, chl, rif, tri/sulf | 0 |
| t314 | 121 | 2 | Ben, tet, tri/sulf | 2 |
| t355 | 152 | 8 | Ben, chl | 7 |
| t5132 | 508 | 1 | Ben | 1 |
| t537 | 3251 | 5 | Ben, tet | 3 |
| t645 | 3250 | 4 | Ben | 4 |
| t827 | 508 | 2 | Ben, tri/sulf | 0 |
| t8453 | 508 | 1 | Ben, tri/sulf | 0 |
| t861 | 508 | 3 | Ben | 0 |
| t8860 | 45 | 1 | Ben | 0 |
| t928 | 250 | 21 | Ben, oxa, gen, kan, tob, cip, tet, chl | 0 |
| t939 | 45 | 1 | Ben | 0 |
| t963 | 15 | 3 | Ben | 1 |
Ben- benzylpenicillin, oxa- oxacillin, gen- gentamicin, kan- kanamycin, tob- tobramycin, cip- ciprofloxacin, tet- tetracycline, chl- chloramphenicol, rif- rifampicin, tri/sulf- Trimethoprim/sulfamethoxazole. The “-” indicates that an isolate was untypeable by MLST.
Carriage of or infection with S. aureus at least once during admission of patients.
| No | p-value | ||
|---|---|---|---|
| Age (years) | 26 | 25 | 0.57 |
| TBSA (median %) | 15 | 16.5 | 0.83 |
| Sex: female (%) | 18 (66%) | 19 (54%) | 0.32 |
| Mortality rate | 5 (18.5%) | 10 (28%) | (RR 0.59; 0.25–1.42) |
*, Mann-Whitney U Test used for analysis
#, Pearson, chi-square used for analysis
RR, relative risk